Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement

Apr

17

Today In Oncology

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia

AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms

Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma

Is Standard of Care Optimal for the Individual Patient?

Advertisement

© 2026 HSP News Service, L.L.C.